两项大型随机试验揭示睾酮治疗的疗效与安全性关键发现
本文叙述性综述整合T Trials与TRAVERSE两项大型随机对照试验,评估睾酮治疗在老年男性中的疗效与安全性。T Trials显示睾酮改善性功能与情绪,但未改善体力或认知功能;TRAVERSE显示主要不良心血管事件(MACE)非劣于安慰剂,但睾酮组骨折率意外升高。
要点
- 睾酮治疗可改善性功能与情绪,但未改善体力或认知功能。
- 高心血管风险男性中,睾酮治疗对MACE非劣于安慰剂。
- 睾酮组骨折率意外高于安慰剂组,需关注骨骼安全性。
核心结论
- 睾酮治疗改善性功能与情绪,但不改善体力或躯体功能。
- 在高心血管风险男性中,睾酮治疗未增加MACE。
- 基于上述数据,对有症状性雄激素缺乏的中老年男性可考虑睾酮治疗以针对已证实有效的症状。
研究设计与样本
- 叙述性综述,整合T Trials与TRAVERSE两项大型随机对照试验。
- T Trials评估≥65岁年龄相关症状性雄激素缺乏男性的睾酮治疗疗效。
- TRAVERSE评估45-80岁高心血管风险男性睾酮治疗的长期心血管安全性。
- 两项试验还评估了前列腺与骨骼安全性。
主要发现
- T Trials中,与安慰剂相比,睾酮治疗改善性功能与情绪,但未改善体力或认知功能。
- TRAVERSE中,睾酮治疗对MACE非劣于安慰剂。
- 前列腺相关事件在两组间相当,但睾酮组骨折率意外升高。
临床怎么用
- 对有症状性雄激素缺乏的中老年男性,可考虑睾酮治疗以针对性功能与情绪症状。
- 对睾酮未改善的结局,可能需要睾酮以外的治疗。
- 高心血管风险男性使用睾酮时,需关注骨折风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Despite widespread use of testosterone therapy, its efficacy and safety in men with age-related low testosterone remain a matter of debate. Elucidating its benefits and risks is essential for clinical decision-making. EVIDENCE ACQUISITION: This narrative review synthesizes evidence from two large randomized controlled trials: the Testosterone Trials (T Trials) and the TRAVERSE trial. The T Trials assessed the efficacy of testosterone treatment in men ≥65 years with age-related syndromic androgen deficiency. The TRAVERSE trial assessed long-term cardiovascular safety of testosterone therapy in men aged 45-80 years with high cardiovascular risk. Prostate and skeletal safety were also assessed. We critically evaluate the design, outcomes, and shortcomings of these trials. EVIDENCE SYNTHESIS: In the T Trials, testosterone therapy, compared with placebo, improved sexual function and mood, but not physical function, vitality, or cognitive function. In the TRAVERSE trial, testosterone therapy was noninferior to placebo with respect to major adverse cardiovascular events (MACE). Prostate-related events were comparable between groups, but fracture rates were unexpectedly higher in the testosterone group. CONCLUSIONS: Results from the T Trials and TRAVERSE trial showed that testosterone therapy improves sexual function and mood but not vitality or physical function. Importantly, it did not increase MACE in men at high risk of cardiovascular disease. Based on these data, treatment with testosterone could be considered in middle-aged and older men with syndromic androgen deficiency to target symptoms where it has demonstrated efficacy, whereas therapies other than testosterone might be warranted for outcomes that were not improved by testosterone.
引用
- Braga M, Basaria S. Key Findings on the Efficacy and Safety of Testosterone Therapy from Two Large Randomized Trials. J Clin Endocrinol Metab. 2026. PMID: 42800050. doi:10.1210/clinem/dgag397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。